EPG Wealth Management LLC Has $1.40 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

EPG Wealth Management LLC trimmed its position in Boston Scientific Co. (NYSE:BSX) by 4.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,650 shares of the medical equipment provider’s stock after selling 649 shares during the quarter. EPG Wealth Management LLC’s holdings in Boston Scientific were worth $1,398,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Colonial Trust Co SC boosted its holdings in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 260 shares during the period. CoreCap Advisors LLC grew its holdings in Boston Scientific by 541.4% in the 4th quarter. CoreCap Advisors LLC now owns 29,282 shares of the medical equipment provider’s stock valued at $2,615,000 after buying an additional 24,717 shares during the last quarter. Crestline Management LP bought a new position in Boston Scientific in the 4th quarter worth approximately $2,974,000. Castle Hook Partners LP lifted its holdings in shares of Boston Scientific by 146.9% during the fourth quarter. Castle Hook Partners LP now owns 762,073 shares of the medical equipment provider’s stock worth $68,068,000 after buying an additional 453,374 shares during the last quarter. Finally, Cetera Investment Advisers boosted its position in shares of Boston Scientific by 4.9% in the fourth quarter. Cetera Investment Advisers now owns 319,161 shares of the medical equipment provider’s stock valued at $28,507,000 after acquiring an additional 14,789 shares during the period. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on BSX. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. Robert W. Baird increased their target price on shares of Boston Scientific from $115.00 to $120.00 and gave the company an “outperform” rating in a research note on Thursday, April 24th. Piper Sandler boosted their price target on Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. BTIG Research reiterated a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. Finally, Citigroup boosted their price objective on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Twenty-three analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $114.52.

Insider Buying and Selling at Boston Scientific

In related news, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares of the company’s stock, valued at approximately $3,441,592.37. This trade represents a 11.77 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the company’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the completion of the transaction, the executive vice president now directly owns 18,705 shares in the company, valued at approximately $1,955,420.70. This represents a 19.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 307,025 shares of company stock worth $31,742,060 over the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Price Performance

Shares of BSX opened at $104.22 on Wednesday. The company has a 50 day moving average of $98.71 and a 200-day moving average of $95.66. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $154.15 billion, a P/E ratio of 83.38, a P/E/G ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a twelve month low of $71.88 and a twelve month high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same period in the previous year, the business earned $0.56 EPS. The company’s revenue was up 20.9% compared to the same quarter last year. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.